Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 13/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 11/20 | 0.47 |
| ▸ | DPP4 | P27487 | 5/20 | 0.47 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037472 | 0.82 | DPP7 (0.49) | DPP7DPP8DPP9DPP4SLC6A15 | |
| SCHEMBL21452248 | 0.82 | ABL1 (0.42) | HCRTR2 | |
| SCHEMBL22966521 | 0.82 | ABL1 (0.42) | HCRTR2 | |
| SCHEMBL28974312 | 0.82 | NOTUM (0.39) | SLC6A9 | |
| SCHEMBL18806154 | 0.81 | NOTUM (0.41) | — | |
| SCHEMBL20249388 | 0.79 | PDGFRB (0.39) | — | |
| SCHEMBL18819906 | 0.79 | CDK6 (0.40) | — | |
| SCHEMBL18806197 | 0.79 | GABRG2 (0.48) | — | |
| SCHEMBL22363433 | 0.76 | NOTUM (0.49) | DPP7DPP8DPP9DPP4SLC6A9 | |
| SCHEMBL20249401 | 0.76 | KDM4E (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | DPP7 590/4885DPP8 560/4885DPP9 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.